Monday, June 14, 2010

HPV and H&N cancer


The RTOG 0129 protocol of altered fractionation with chemo vs. standard fractionation with chemo in head and neck cancers is a negative trial, however, published in the NEJM this week is the results of the trial broken down by prognostic factor. Unsurprisingly HPV plays a large role in oropharynx cancers, and clearly needs to be taken into account when designing future trials.


Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

No comments: